Skip to content


Reyvow (lasmiditan) is a small molecule pharmaceutical. Lasmiditan was first approved as Reyvow on 2020-01-31. It is used to treat migraine with aura and migraine without aura in the USA. It is known to target 5-hydroxytryptamine receptor 1F. Reyvow's patent is valid until 2037-12-05 (FDA).
Trade Name Reyvow
Common Name Lasmiditan
Indication migraine with aura, migraine without aura
Drug Class Antimigraine (5-HT1 receptor agonists)
Get full access now